Therapeutic Areas |
Psychiatry
Psychiatry
|
Latuda® (lurasidone HCI)
Psychiatry
|
Resources
Psychiatry
|
Disease State
Psychiatry
|
Disease State
|
Bipolar Depression
Psychiatry
|
Disease State
|
Schizophrenia
Psychiatry
|
Disease State
|
General Psychiatry
Psychiatry
|
Latuda® (lurasidone HCI)
|
Publications
Therapeutic Areas |
Neurology
Neurology
|
Aptiom® (eslicarbazepine acetate)
Neurology
|
Kynmobi® (apomorphine hydrochloride)
Neurology
|
Resources
Neurology
|
Disease State
Neurology
|
Disease State
|
Parkinson's
Neurology
|
Disease State
|
Epilepsy
Neurology
|
Disease State
|
General Neurology
|
Publications
|
Publications
Therapeutic Areas |
Respiratory
Respiratory
|
Brovana® (arformoterol tartrate)
Respiratory
|
Lonhala® Magnair® (glycopyrrolate)
Respiratory
|
Xopenex HFA® (levalbuterol tartrate)
Respiratory
|
Resources
Respiratory
|
Disease State
Respiratory
|
Disease State
|
COPD
Respiratory
|
Disease State
|
General Respiratory
|
Publications
|
Publications
|
Publications
Submit Medical Inquiry
Engage With Field Medical
Resources
Adverse Event & Product Complaint Reporting
Pipeline
| SEP-363856
| SEP-363856 | Schizophrenia 4 Weeks
| SEP-363856 | Schizophrenia 26 Weeks
| SEP-363856 | PD Psychosis 6 Weeks
| SEP-4199
| SEP-4199 | 6 Week
Search Medical Information
Scientific Conferences
Search Medical Information
Psychiatry
Neurology
Respiratory
Home
Therapeutic Area
Psychiatry
Neurology
Respiratory
submit medical inquiry
Engage With Field Medical
resources
adverse event & product complaint reporting
pipeline
back
Graphical Assets
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
Ohar JA, et al.
Efficacy and Safety of a Novel, Nebulized Glycopyrrolate for the Treatment of COPD: Effect of Baseline Disease Severity and Age; Pooled Analysis of GOLDEN 3 and GOLDEN 4
Ohar JA, et al.
Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
Siler TM, et al.
In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow
®
Closed System and Tiotropium Delivered in the HandiHaler
®
Ohar JA, et al.
Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
Putcha N, et al.
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
Hanania NA, et al.
Publications
YOU ARE NOW LEAVING SUNOVIONMEDICAL.COM
Sunovion makes no representation as to the accuracy or any other aspect of the information contained in or on the above non-Sunovion sites, sources or servers, nor does Sunovion necessarily endorse such sites or sources.
ok
cancel
>
>
>
opt-in to communications from Sunovion
First Name
Last Name
Email
Phone Number
By checking this box, I agree and acknowledge that the information I’ve provided voluntarily will be used only by Sunovion and its contracted third-parties to contact me regarding my request. I understand that Sunovion will not sell or transfer my name to any third party for their marketing use. Please see the most recent version of our privacy notice, which may change from time to time.
Submit
contact us
Sunovion Pharmaceuticals Inc.
Medical Information
84 Waterford Drive
Marlborough, MA 01752
1-800-739-0565
minfo@sunovion.com
Global Medical Information
CANADA
Sunovion Pharmaceuticals Canada Inc.
Medical Information
1-866-260-6291, option 2
sunovionmedinfo@solutionsinhealth.com
OTHER COUNTRIES
Sunovion Pharmaceuticals Inc.
Medical Information
800-739-0565
minfo@sunovion.com
For information about the collection and use of your personal information, please visit
www.sunovion.com/HCPprivacynotice
THANK YOU
Thank you for rating SunovionMedical.com
close
HCP/FDM Confirmation
Please confirm below to continue
I confirm that I am a Health Care Professional (HCP) practicing in the United States, or acting on behalf of an HCP
OR
I am a Formulary Decision Maker (FDM) and/or working on behalf of a public or private payer organization to review scientific information to make drug or device selection or acquisition, formulary management, or coverage and reimbursement decisions on a population basis.
YOU ARE NOW LEAVING SUNOVIONMEDICAL.COM
You are now leaving SunovionMedical.com
ok
cancel